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Abstract
Replication-competent (oncolytic) adenoviruses (OAV) can be adapted as vectors for the delivery of therapeutic
genes, with the aim of extending the antitumor effect beyond direct cytolysis. Transgene expression using these
vectors is usually intense but short-lived, and repeated administrations are hampered by the rapid appearance of
neutralizing antibodies (NAbs). We have studied the performance of monocytes as cell carriers to improve
transgene expression in cancer models established in athymic mice and immunocompetent Syrian hamsters.
Human and hamster monocytic cell lines (MonoMac6 and HM-1, respectively) were loaded with replication-
competent adenovirus-expressing luciferase. Intravenous administration of these cells caused a modest increase
in transgene expression in tumor xenografts, but this effect was virtually lost in hamsters. In contrast, in-
tratumoral administration of HM-1 cells allowed repeated cycles of expression and achieved partial protection
from NAbs in preimmunized hamsters bearing pancreatic tumors. To explore the therapeutic potential of this
approach, HM-1 cells were loaded with a hypoxia-inducible OAV expressing the immunostimulatory cytokine
interleukin-12 (IL-12). Three cycles of treatment achieved a significant antitumor effect in the hamster model, and
transgene expression was detected following each administration, in contrast with the rapid neutralization of the
free virus. We propose monocytes as carriers for multiple intratumoral administrations of armed OAVs.
Introduction
Oncolytic viruses (OV) are natural or modified viruseswith the ability to preferentially replicate in and destroy
cancer cells, in comparisonwith the surrounding normal cells.
The number of different types of viruses proposed for the
treatment of cancer is continuously expanding, in search of
agents with the optimal balance between potency and speci-
ficity. However, the experience accumulated with early ver-
sions of these agents indicates that the immune system and
physical barriers in the tumor microenvironment are impor-
tant obstacles for the spread and amplification of OVs, espe-
cially in the clinical setting (Eager and Nemunaitis, 2011). To
overcome these limitations, OVs have been adapted as vectors
for the expression of therapeutic genes, with the aim of in-
creasing their oncolytic effect (pro-apoptotic or suicide genes),
or to gain a systemic antitumor effect (cytokines, tumor anti-
gens, etc.). In fact, some of themost promising results in recent
clinical trials involve the use of OVs expressing the im-
munostimulatory cytokine granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Lei et al., 2009; Senzer et al.,
2009; Breitbach et al., 2011). This approach may alleviate the
need for efficient biodistribution of the virus in the tumor, but
the appearance of neutralizing antibodies (NAb) remains a
serious obstacle to maintain the function of the virus in re-
peated administrations. The influence of the immune system
on OVs is especially relevant in the case of highly immuno-
genic agents such as oncolytic adenoviruses (OAV), which, on
the other hand, are efficient gene therapy vectors (Alemany
and Cascallo, 2009).
The tumor tropism of certain cell types has stimulated their
use as carriers for OVs, with the double purpose of achieving
tumor targeting upon systemic administration and shielding
the virus from NAbs. These cells include different kinds of
stem cells such as mesenchymal (Dwyer and Kerin, 2010),
adipose ( Josiah et al., 2010) or neural stem cells (Ahmed et al.,
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2011), as well as lymphocytes (Thorne et al., 2010), mono-
cytes/macrophages (Muthana et al., 2011) or tumor cells
(Raykov and Rommelaere, 2008). In general terms, cells de-
rived from the hematopoietic system are more suited to es-
cape from anatomical filters such as lungs and liver, whereas
epithelial cells are more efficient in OAV amplification and
release. Monocytes are an attractive option because they ac-
cumulate in the hypoxic areas of tumors, and they can be
loaded with viruses designed to be activated in response to
hypoxia-inducible pathways (Muthana et al., 2011). The use of
autologous cells ensures their compatibility with the recipient,
but increases the cost and complicates the logistics of the
treatment. In contrast, approaches based on cell lines are
easier to standardize and could be suitable if long-term ex-
pression of the transgene is not required (Liu et al., 2010).
The concept of tumor homing has been extensively dem-
onstrated in preclinical studies, although unbiased quantifi-
cation of the percentage of carrier cells that reach the tumor
upon systemic administration is seldom reported. In addition,
the relevance of animal models is an important issue in the
case of OAV, since mice are not permissive for human ade-
novirus. Specificity of OAV replication, and hence transgene
expression, are usually overestimated in human tumor xeno-
grafts established in athymic mice, and the defects in the
immune system of the host complicates the evaluation of the
protective role of carrier cells. In the present work, we have
used the Syrian hamster as an immunocompetent, permissive
model (Thomas et al., 2006; Bortolanza et al., 2007).
The aim of this study, rather than searching for an ideal
cell candidate, was to evaluate the properties of a represen-
tative cell line, with special focus on the analysis of tumor
transduction. Therefore, we used materials relatively simple
and easy to standardize, such as monocytic/macrophage cell
lines and a replication-competent adenovirus expressing
luciferase without tumor specificity. This allowed us to reach
several conclusions that can be applied to different thera-
peutic approaches. In contrast with xenografts, tumor hom-
ing of virus-loaded monocytes was virtually undetectable
following systemic administration in hamsters. However,
we provide evidence that these cells can be used to protect
the virus from NAbs and preserve the efficacy of repeated
intratumoral administrations. When these cells were
loaded with a hypoxia-inducible OAV expressing the im-
munostimulatory cytokine interleukin-12 (IL-12), we dem-
onstrated improved transgene expression and antitumor
effect compared with the administration of the free virus.
Materials and Methods
Cells
The human hepatocellular carcinoma (HuH-7; JCRB
Genebank, Japan) and Syrian hamster pancreatic cancer
(HaP-T1) tumor cell lines (German Collection of Micro-
organisms and Cell Cultures DSMZ ACC 222) were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS). The Syrian
hamster macrophage cell line HM-1 ( JCRB Genebank, Japan)
was maintained in Roswell Park Memorial Institute medium
(RPMI) supplemented with 10% FBS. The human monocyte/
macrophage cell lines Mono-Mac-6 (here designated MM6)
and acute monocytic leukemia (THP-1) were obtained from
the German Collection of Microorganisms and Cell Cultures
(DSMZ, ACC 124) and the American Tissue Culture Collec-
tion (ATTC, TIB-202), respectively. These cells were main-
tained in RPMI supplemented with 10% FBS plus 2mM
L-glutamine, nonessential amino acids, and 1mM sodium
pyruvate. MM6 were supplemented with 10lg/ml human
insulin. Human monocytes were isolated from buffy coats
using CD11c microbeads (Miltenyi Biotech) and the auto-
MACS Pro separator according to manufacturer instructions.
All culture media were supplemented with 100U/ml peni-
cillin, 100lg/ml streptomycin, and 2mM L-glutamine. All
cells were maintained at 37C with 5% CO2 in a humidified
incubator.
Viruses
TheAd-CMV-Luc virus (Vector Biolabs) is a first-generation,
replication-deficient adenovirus-expressing luciferase under
the control of the cytomegalovirus (CMV) promoter. The
same promoter controls the expression of the green fluores-
cent protein (GFP) in the first-generation adenovirus-
expressing GFP (Ad-GFP) virus, as previously described
(Narvaiza et al., 2006). The Ad-WTLuc virus (Bortolanza
et al., 2009a) is based on wild-type adenovirus type 5 (Ad5)
with insertion of the luciferase gene into the E3 region
(substitution of the E3-6.7 K/gp19K genes). This location
determines that luciferase expression is under the control
of endogenous viral promoters and is dependent on viral
replication (Hawkins et al., 2001). Ad-IL12G is an OAV
derived from the previously described Ad-DHscIL12 virus
(Bortolanza et al., 2009b). Both versions contain the murine
single-chain IL-12 as a transgene in the E3 locus and a partial
deletion of the E1A gene (comprising bp 922 to 947) to obtain
preferential replication in cancer cells (Fueyo et al., 2000;
Heise et al., 2000).
Modifications in Ad-IL12G were designed to obtain a
more compact genome. They include restoration of the wild-
type E4 promoter and incorporation of a smaller promoter in
the E1A region, containing 3 hypoxia-response elements
(HREs) instead of the nine copies present in the previous
version. No differences in hypoxia responsiveness were ob-
served between both promoters using luciferase reporter
plasmids (not shown). All viruses were amplified in 293 cells
and purified by ultracentrifugation in cesium chloride (CsCl)
gradient. Quantification of infectious units (iu) was done
using the Adeno-X rapid titer kit (Clontech).
Infectivity assay
Cells were infected with different multiplicity of infection
(MOIs) of the Ad-GFP virus, and 24 hr later the percentage of
cells expressing GFP was analyzed using a FACScan flow
cytometer (BD Biosciences).
In vitro viral replication assay. Cells (5· 104/well) were
cultured in 24-well plates overnight and then incubated for
12hr in 300ll of medium containing 2% FBS and the indicated
amounts of viruses. After intensive washing with phosphate-
buffered saline (PBS), cells were maintained in 500ll of virus-
free medium for different periods. Then, cells and supernatants
were collected separately and cells were lysed by three
cycles of freezing and thawing. The amount of viruses in
supernatants and cell lysates was quantified by end-limiting
dilution on 293 cells and expressed in total iu per well.
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Tumor models and treatments
Xenografts were induced in the flank of 5–6 week-old
athymic nu/nu mice (Charles River Laboratories) by subcu-
taneous inoculation of 107 HuH-7 cells. When tumors
reached a volume of 500–700mm3, animals were treated
with viruses or virus-loaded carrier cells. For intravenous
administrations, MM6 or HM-1 cells were infected ex vivo
with the indicated MOIs of Ad-WTLuc for 4 hr. Virus was
then intensively washed out with PBS. Viability of cells was
verified by trypan blue exclusion and they were resuspended
in 200 ll saline solution before tail vein injection. The same
procedure was carried out for intratumoral administration,
except that infection was extended for 24 hr and cells were
resuspended in 50ll saline solution before injection.
Liver metastases of pancreatic cancer were established in
Syrian (Golden) hamsters (Mesocricetus auratus, HSD HAN:
AURA, 5 weeks of age; Harlan) by intrahepatic injection of
3 · 106 HaP-T1 cells through laparotomy, as previously de-
scribed (Bortolanza et al., 2007). Intravenous inoculation of
viruses or virus-loaded carrier cells was performed by retro-
orbital injection. Intratumoral inoculations were performed
by direct injection through laparotomy for single inocula-
tions. Repeated intratumoral inoculations were performed
by ultrasound-guided percutaneous injection using a dedi-
cated small-animal high-resolution ultrasound imaging unit
(VEVO 770; Visualsonics), as previously described (Zabala
et al., 2009). Ex-vivo infection of carrier cells with Ad-WTLuc
was performed as described above. In the case of the Ad-
IL12G virus, HM-1 cells were placed in hypoxia chambers
(1% O2, 94% N2, 6% CO2; Billups Rothenberg Inc.) during
infection.
Tumor volumes were calculated at necropsy using the
formula V = (Dxd2)/2, where D and d are the major and
minor diameters, respectively. Blood samples were obtained
by retro-orbital sinus blood extraction. All procedures were
carried out following protocols approved by the local ethical
committee in accordance with recommendations for proper
care and use of laboratory animals.
Quantification of luciferase activity in vitro. Cells (5x104/
well) were cultured in 24-well plates overnight and then
incubated for 12 hr in 300 ll of medium containing 2% FBS
and the indicated amounts of viruses. After intensive
washing with PBS, cells were maintained in 500 ll of virus-
free medium. Cell lysates were collected 48 hr later, and lu-
ciferase activity was analyzed using the Luciferase Assay
System (Promega).
Quantification of neutralizing antibodies. Anti-adenovirus
type 5 neutralizing antibodies were determined using a
modified luciferase-based virus neutralization assay, as pre-
viously described (Fontanellas et al., 2010).
In vivo bioluminescence detection. Ten minutes before
luciferase detection, mice and hamsters received an intra-
peritoneal injection of 100ll or 300ll D-Luciferin Firefly
(Sigma), respectively. Animals were anesthetized and placed
in a dark chamber connected to a cooled charged coupled
device (CCD) camera (IVIS, Xenogen). Photon emission
was quantified and analyzed using Living Image Software
(Caliper).
Quantification of murine IL-12 in serum. An OptEIA
mouse IL-12 ELISA kit was used (BD Biosciences) according
to the manufacturer’s instructions.
Analysis of CCR2 and CCR5 expression. Cells (5· 104/
well) were left untreated or exposed to Ad-WTLuc or IFNa2b
(100 U; Sicor Biotech) 4 hr before extensive washing. Sixteen
hours later, cells were fixed with 0.25% paraformaldehyde
and stained with the following fluorochrome-conjugated
antibodies: CD192 (TG5/CCR2, Biolegend); CD195 (eBio
T21/8, eBioscience), and CD14 (M5E2, BD Bioscience). Ac-
quisition was performed in a FACSCalibur flow cytometer
and was analyzed using FlowJo software (Tree Star).
Quantification of flourescence-labeled cells in tissues. MM6
cells were mock-infected or infected with Ad-WTLuc at MOI
1000 for 4 hr before extensive washing. Cells were then
labeled with 2.5 lM carboxyfluorescein succinimydil
ester (CFSE; Sigma) for 15min and washed again. A total of
4 · 106 cells were injected intravenously or intratumorally in
athymic mice-bearing subcutaneous HuH-7 xenografts.
Twenty-four hours later, livers and tumors were extracted
and treated with 400U/ml collagenase D and 50lg/ml
DNAse I (Roche Diagnostics). After mechanical tissue dis-
sociation, cells were passed through a 70 lm nylon mesh
filter (BD Biosciences) and washed. To enrich liver cell
suspension in leucocytes, hepatocytes were removed with
Percoll gradient. Red blood cells were lysed with AcK buffer.
CFSE + cells were quantified by flow cytometry as described
above.
Statistical analysis
The Mann Whitney test was applied for statistical com-
parisons between two groups. Analysis was performed using
the GraphPad Prism program (GraphPad Software).
Results
Infectivity, transgene expression, and replication
of human adenovirus in monocytic cell lines
The infectivity of the different cells used in this study was
evaluated using an Ad-GFP. The percentage of GFP + cells
was quantified by flow cytometry 24 h after initiation of in-
fection. As shown in Figure 1A, epithelial-derived cancer cell
lines from human (HuH-7) or hamster (HaP-T1) origin were
efficiently infected with Ad-GFP at relatively low MOIs (in-
fectivity of 50% or higher at MOI 10). In contrast, the
monocytic cell line MM6 required high MOIs, and the per-
centage of infected cells remained below 25%. The same was
observed with freshly isolated human monocytes (HuM).
Interestingly, the hamster monocytic cell line HM-1 was
efficiently infected at MOI 100.
Next, we evaluated the ability of cells to support transgene
expression mediated by a replication-competent adeno-
virus. To this end, we compared the activity two vectors
carrying the luciferase gene. Ad-CMV-Luc is an E1-deleted,
replication-defective adenoviral vector, whereas Ad-WTLuc
has no restrictions for replication and contains the transgene
in the E3 region. Cells were infected at suboptimal MOIs
(2, 1, 25, and 250 for HaP-T1, HuH-7, HM-1, and MM6,
respectively) to better appreciate the influence of virus
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replication. We observed a dramatic increase in luciferase
activity in cells infected with the replicative vector compared
with the defective counterpart, even in those that were rel-
atively refractory to adenoviral infection (Fig. 1B).
To further demonstrate replication of adenovirus in
monocytic cells, we infected HuH-7 and HM-1 cells with Ad5
and determined the progression of viral progeny production
over time (Fig. 1C and D, respectively). In agreement with
active virus amplification and spread, we detected an initial
increase in the amount of virus in cell lysates with a subse-
quent decline at day 6, when most cells in each well are
already destroyed. In fact, release of virus in the supernatant
peaked at this time in both cell lines. Note that the parallel
amplification of cells and viruses explains the high titers
obtained at late times.
Monocytes improve the biodistribution of adenovirus
in human tumor xenografts established in athymic mice
In order to estimate the potential of MM6 cells as carriers
for OAV, we analyzed the expression of key chemokine re-
ceptors involved in the trafficking of monocytes to tumor
sites: CCR2, the ligand for CCL2 (monocyte chemoattractant
protein-1, MCP-1) and CCR5, the ligand for CCL5 (RANTES)
(Murdoch and Lewis, 2005). Using flow cytometry we found
that more than 70% of MM6 were positive for the monocytic
marker CD14 (not shown). Among CD14+ MM6 cells, more
than 80% were positive for CCR2, which is similar to the
percentage observed in primary human monocytes (Sup-
plementary Fig. 1A; Supplementary Material available online
at www.liebertonline.com/hum).
Regarding CCR5, approximately 40% of CD14 + MM6
displayed this receptor on their surface, which is actually
higher than in primary monocytes. Compared with other
commonly used human monocytic cell lines (THP-1), the
expression of CCR2 and CCR5 was also higher in MM6,
suggesting that this cell line is suitable for tumor homing.
Adenoviral infection could alter the expression of these re-
ceptors, either directly or in response to the production of
cytokines such as type I interferon. In order to check this
possibility, we repeated the analysis in MM6 cells infected
with Ad-WTLuc or treated with human interferon-alpha
(IFNa). As shown in Supplementary Figure 1B, we found no
reduction in the percentage of cells displaying CCR2 or
CCR5 under these conditions. The intensity of expression
was not affected either (not shown), suggesting that MM6
cells retain their capacity to sense chemotactic factors despite
Ad5 infection.
The first function evaluated in vivo in the monocytic cell
lines was their ability to deliver a replication-competent
adenovirus to distant tumors following intravenous admin-
istration. Tumors were established by subcutaneous
FIG. 1. Human and hamster monocytes support infection, replication, and transgene expression of adenoviral vectors. (A)
Freshly isolated human monocytes (HuM); monocytic/macrophage cell lines from human (MM6) or hamster (HM-1); the
human hepatocarcinoma cell line HuH-7, or the hamster pancreatic cell line HaP-T1 were infected with the first-generation
adenovirus-expressing green fluorescent protein (Ad-GFP) vector at the indicated multiplicity of infection (MOIs). The
percentage of GFP + cells was determined by flow cytometry 24 h later. (B) The indicated cell lines were infected with the
Ad-WTLuc or Ad-CMV-Luc vector at MOIs 2, 1, 25, and 250 for HaP-T1, HuH-7, HM-1, and MM6, respectively. Cell lysates
were collected at 48 h post-infection for quantification of luciferase activity, expressed in relative light units/lg protein. (C, D)
HuH-7 and HM-1 cells were infected with Ad5 at MOI 2 and 100, respectively, and viral progeny production was quantified
in cell lysates and supernatants (sup) collected at the indicated days post-infection. **p < 0.001.
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inoculation of HuH-7 in athymic mice. The MM6 or HM-1
cells were infected ex vivo with the Ad-WTLuc virus for 4 hr,
and then the virus was removed and 4· 106 cells were ad-
ministered by tail vein injection into different groups of mice.
Another group received the free virus using the same route.
Note that the dose of virus administered in each case cannot
be directly compared. We injected 2 · 108 iu of the free virus,
which is 2–20 times lower than the titer employed for ex-vivo
infection of HM-1 and MM6 cells, respectively. However,
only a small portion of these virions actually infects the cells,
and the majority is washed away before inoculation. In fact,
more than 90% of the infective viral particles are detected in
the supernatant that is discarded after the first centrifugation
of cells (data not shown).
Transgene expression was analyzed in vivo by biolumi-
nescence detection (BLI) over the next 2 weeks. At early time
points (3 days after administration), we could only detect
luciferase activity in the tumors of mice that received the
virus incorporated in carrier cells (Fig. 2A). In contrast,
transgene expression from the free virus was almost exclu-
sively hepatic, indicating that monocytes reduced the off-
target liver transduction of adenovirus. Despite this sharp
difference, it became evident that tumor targeting achieved
by monocytes was modest, with approximately 10% of the
total BLI corresponding to the tumors and the majority still
coming from the liver (Fig. 2B).
Similar results were obtained when treatments were ad-
ministered by retro-orbital injection (not shown). We re-
peated the same experiment using a higher amount of carrier
cells (12· 106 MM6 cells/mouse). Under these circumstances,
tumor transduction improves dramatically (see Fig. 2B,
‘‘high dose’’), but there is a parallel increase in hepatic
homing of cells. Regarding the administration of free Ad-
WTLuc virus, only when the dose reaches 2· 109 iu/mouse
(which caused 25% mortality in athymic mice) we detected
comparable luciferase expression in tumors, but liver trans-
duction was extremely high (light emission of more than 1011
photons/sec).
In Figures 2C and 2D we represent the BLI quantification
over time in the tumor and liver, respectively, corresponding
the low dose of treatments. It is important to note that the
absence of an efficient antiviral response in athymic mice,
and the fact that only the xenografts support viral replica-
tion, lead to a misleading perception of OAV specificity in
tumors at late time points. In fact, transgene expression
slowly decreases in the liver but increases in the tumor due
to viral amplification. Under these circumstances, even the
free virus seems to accumulate in tumors one week after
intravenous injection (Fig. 2C).
In order to estimate the proportion of cells or free virus
that reaches the tumor upon systemic administration, the
same doses were injected intratumorally in HuH-7 xeno-
grafts. Evaluation of transgene expression was performed as
described for the intravenous administration (Fig. 3). The
results indicate that virus-loaded monocytes can efficiently
express the transgene in the tumor at day 3 (Fig. 3A and B).
Luciferase activity was restricted to the tumor, and the BLI
intensity was similar to that obtained by intratumoral ad-
ministration of the free virus. If we take into account that
transgene expression in tumors is 100 to 1,000 times higher if
cells are administered locally versus systemically (compare
Figs. 2B and 3B), we can conclude that only a small pro-
portion (usually less than 1%) of carrier cells reach their
target. Similar results were obtained when we used freshly
isolated monocytes from human donors (not shown). This
percentage is much lower (less than 0.01%) in the case of the
free virus.
To investigate if the relatively poor tumor homing of
monocytes could be a consequence of adenovirus infection,
MM6 cells were mock-infected or infected with Ad-WTLuc
and then labeled with CFSE before intravenous administra-
tion. The same amount of labeled cells was injected in-
tratumorally in another set of animals. The abundance of
CFSE + mononuclear cells was analyzed 24 hr later in liver
and tumor homogenates. In accordance with BLI data, the
amount of cells detected in tumors following i.v. adminis-
tration was only 1% compared with local injection, and this
percentage was not altered by adenoviral infection (Supple-
mentary Fig. 2).
Monocytes are not efficient carriers for systemic
delivery of adenovirus in Syrian hamsters
In order to evaluate the performance of carrier cells in
immunocompetent animals permissive for adenovirus rep-
lication, we used a model of pancreatic cancer in Syrian
hamsters. First, we established subcutaneous tumors by in-
oculation of HaP-T1 cells to study the tumor homing abil-
ity of cells, as previously described for athymic mice. Free
Ad-WTLuc virus or virus loaded in HM-1 carrier cells were
administered systemically by retro-orbital injection. In con-
trast with the results obtained in athymic mice, no significant
tumor transduction was observed, and expression of the
transgene was almost exclusively hepatic. In Figure 4, we
depict an experiment performed with 5· 107 cells. The effect
was similar when we duplicated the number of cells, and
there was no progressive amplification of luciferase expres-
sion in any organ (not shown), in line with previous de-
scription of Ad-WTLuc infection in hamsters (Bortolanza
et al., 2009a).
Local administration of virus-loaded monocytes allows
repeated transgene expression in pancreatic tumors
of Syrian hamsters
Since we could not demonstrate tumor targeting of
monocytes upon systemic administration in hamsters, we
studied their potential applications in local delivery. In this
case, tumors were established by implantation of HaP-T1 in
the liver of hamsters, to evaluate the feasibility of this
approach for the treatment of internal organs. The first
objective was to evaluate if monocytes can improve the
efficacy of multiple administrations of OAV. In this case, ex-
vivo infection of cells was extended for 24 hr, to ensure
active expression of the transgene at the moment of injec-
tion. The hamster received two intratumoral administrations
of free Ad-WTLuc or virus loaded in HM-1 cells, separated
13 days.
As shown in Figure 5A, the free virus was very efficient in
the initial tumor transduction, but the second injection
caused no significant elevation in BLI. In contrast, carrier
cells achieved a second peak of transgene expression after re-
administration. To better appreciate this difference, in Figure
5B we represent the quantification of light emission the day
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FIG. 2. Monocytes improve adenovirus-mediated transduction of tumors following systemic administration in athymic
mice. Tumors were established in athymic mice by subcutaneous inoculation of HuH-7 cells. MM6 or HM-1 cells were
infected ex vivo with Ad-WTLuc at MOI 1,000 and 100, respectively. Cells were administered intravenously in two groups of
mice (n = 5) that received 4 · 106 cells (low dose) or 1.2 · 107 cells (high dose) (n = 5). Other groups received 2 · 108 iu or 2· 109
iu of the free virus (designed as low and high dose virus, respectively). Transgene expression in liver and tumors was
quantified over time by bioluminescence detection (BLI). Representative images of mice in the low-dose groups (A) and
average light emission in liver and tumor 3 days after treatment in all groups, expressed in photons/second (B). Follow-up of
light emission in the tumor (C) and liver (D) of animals corresponding to the low-dose groups. In the artificial color code, the
most intense light emission is represented in red and the lowest in blue. Standard deviation is represented in all cases.
*p < 0.05.
FIG. 3. Intratumoral injection of virus-loaded monocytes achieves efficient tumor transduction. Tumors were established in
athymic mice by subcutaneous inoculation of HuH-7 cells. MM6 or HM-1 cells were infected ex vivo with Ad-WTLuc at MOI
1,000 and 100, respectively, and 4· 106 cells were administered intratumorally (n = 5). The other group (virus) received 2· 108
iu of the free virus. Transgene expression in liver and tumors was quantified over time by BLI. Representative images of mice
(A) and average light emission in liver and tumor 3 days after treatment, expressed in photons/second (B). Follow-up of light
emission in the tumor (C) and liver (D) of the indicated groups.
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before (pre-) and the day after (post-) the second inoculation.
These results suggest that carrier cells could either avoid the
production of NAbs against adenovirus or protect Ad-
WTLuc from them. Thus, we set up experiments to clarify
this point and determine if carrier cells can allow tumor
transduction in animals previously exposed to adenovirus,
which is a clinically relevant scenario.
A group of hamsters received an intravenous dose of Ad5
(‘‘immunized’’ animals), and one month later Ad-WTLuc or
virus-loaded HM-1 cells were inoculated in the hepatic tu-
mors, as previously described. A different set of hamsters
received the same treatments, but were not pre-exposed to
adenovirus (‘‘naı¨ve’’ animals). Luciferase expression was de-
termined by BLI 24hr after intratumoral injections, and the
presence of NAbs was quantified in the serum of animals
before the treatment and 2 weeks later. As shown in Figure
6A, intratumoral administration of Ad-WTLuc in naı¨ve
hamsters stimulated the production of high titers NAbs
(> 1,000). The use of carrier cells caused a small decrease in
NAbs (average titer of approximately 700), but titers were
significantly increased versus control animals, demonstrating
that the virus was efficiently detected by the immune system.
In the case of preimmunized hamsters, the same tendency
was observed, with a boost of NAbs caused by the in-
tratumoral inoculation of Ad-WTLuc and, to a lesser extent,
virus-loaded monocytes. In terms of transgene expression, it
became evident that immunization caused a dramatic de-
crease in tumor transduction of the free virus (more than
8,000-fold inhibition). In contrast, virus carried in HM-1
cells was partially protected, with an 8-fold inhibition of
luciferase expression in immunized versus naı¨ve animals
(Fig. 6B).
Monocytic carrier cells increase the therapeutic effect
of an OAV-expressing IL-12
Once we had demonstrated that HM-1 cells improve the
function of replication-competent adenoviral vectors in pre-
immunized hosts, we studied if they could also increase the
antitumor effect of an OAV expressing a therapeutic gene.
For this purpose, we used Ad-IL12G, a hypoxia-inducible
vector carrying a single-chain version of the murine im-
munostimulatory cytokine IL-12 (Bortolanza et al., 2009b).
This virus contains a hypoxia-responsive promoter control-
ling the expression of the E1A region to enhance its activity
in tumor tissues. In addition, a partial deletion in the E1A
gene (encompassing conserved region 2) was introduced to
avoid inactivation of pRB in the cells. This modification
causes a relative blockade of adenoviral replication in normal
quiescent cells, as previously described (Fueyo et al., 2000;
Heise et al., 2000).
First we verified that HM-1 cells infected with Ad-IL12G
produced high amounts of IL-12 under hypoxic conditions
(Supplementary Fig. 3). The biological function of murine IL-
12 on Syrian hamsters has been previously demonstrated
(Bortolanza et al., 2009b). For in vivo evaluation of the anti-
tumor effect, we used a stringent model consisting on pre-
immunized hamsters bearing HaP-T1–derived tumors in the
liver. A schematic representation of the experiment is de-
picted in Figure 7A. Twenty days before tumor implantation,
animals received an intravenous injection of Ad5. Intra-
tumoral administration of Ad-IL12G or virus-loaded HM-1
cells was repeated three times on days 6, 8, and 13 after
tumor implantation. Blood collection was performed at the
indicated days for quantification of IL-12 concentration and
titer of NAbs. In agreement with results obtained with the
reporter gene luciferase, discrete peaks of IL-12 concentration
were observed following each administration of Ad-IL12G-
loaded cells (Fig. 7B). The intensity was progressively
FIG. 4. Inefficient tumor transduction of tumors following
systemic administration of virus-loaded monocytes in Syrian
hamsters. Tumors were established by subcutaneous inocu-
lation of HaP-T1 cells in Syrian hamsters. HM-1 cells were
infected ex vivo with Ad-WTLuc at MOI 100, and 5 · 107 cells
were administered intravenously (n = 5). The other group
(virus) received 2· 109 iu of the free virus. Transgene ex-
pression in liver and tumors was quantified over time by
BLI. (A) Representative images of hamsters in both groups
(HM-1 top; virus bottom) 3 days after treatment. Dorso-
lateral view to show the tumor (left panels) and ventral
view to better appreciate the signal in liver (right panels).
(B) Average light emission in both groups, expressed in
photons/second.
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attenuated, but at least three cycles of treatment are effective
in these preimmunized animals.
In sharp contrast, injection of the free virus caused only a
marginal increase in IL-12 (less than 1 ng/ml, not re-
presented in the graphic). This difference was not due to a
reduction in NAbs, because both groups showed a strong
increase in titers following the third dose of treatment (Fig.
7C). More importantly, necropsies performed 3 weeks after
initiation of treatment revealed a significant reduction in
tumor growth in the group of hamsters treated with carrier
cells (Fig. 7D). In summary, our results suggest that mono-
cyte/macrophage cell lines used as carriers for armed OAVs
allow repeated cycles of transgene expression and increase
the therapeutic effect of these agents in immunocompetent
subjects.
Discussion
Treatment of disseminated tumors with OAVs that rely
mainly on their direct oncolytic effect will require carrier cells
with a marked tumor tropism, especially if accumulation of
virus can be toxic in normal tissues such as liver or lungs.
Our data indicate that monocytes do not match this re-
quirement. The percentage of systemically administered
carrier cells that reach a distant tumor is not usually reported
in the literature. Here we provide a relative estimation based
on the comparison of transgene expression when the same
number of cells is administered intravenously or in-
tratumorally. Even in our xenograft tumor model, barely 1%
of the total number of intravenously injected monocytes
reaches a subcutaneous tumor. We corroborated this data
FIG. 5. Monocytes improve the efficacy of repeated administrations of adenovirus in Syrian hamsters. Tumors were
established by intrahepatic inoculation of HaP-T1 cells in Syrian hamsters. HM-1 cells were infected ex vivo with Ad-WTLuc
at MOI 100, and 1 · 107 cells were administered intratumorally (n = 5). The other group (virus) received 5 · 108 iu of the free
virus. The same treatments were repeated 13 days later (re-administration). Transgene expression in tumors was quantified
over time by BLI. (A) Progression of light emission in tumors, expressed in photons/second. (B) Comparison of transgene
expression the day before (pre, white bars) and 24 hr after re-administration (post, black bars) in both groups of hamsters.
*p < 0.05.
FIG. 6. Monocytes improve local tumor transduction in adenovirus-immunized hamsters. Syrian hamsters received an
intravenous injection of saline solution (naı¨ve) or 5· 108 iu of Ad5 (immunized). One month later, tumors were established in
both groups of animals by intrahepatic inoculation of HaP-T1 cells. A subset of naı¨ve and immunized hamsters received an
intratumoral injection of 1· 107 HM-1 cells infected ex vivo with Ad-WTLuc at MOI 100 (n = 7), or 5 · 108 iu of the free Ad-
WTLuc virus. (A) Quantification of anti-adenovirus NAbs in the serum of hamsters 2 weeks after treatments. Control groups
indicate the titer of naı¨ve or immunized animals before the treatments. (B) Comparison of transgene expression (luciferase
activity) in tumors of naı¨ve or immunized hamsters 24 hr after treatment with free virus or HM-1 carrier cells. *p < 0.05;
**p < 0.001; ***p < 0.0001.
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by direct quantification of CFSE-labeled cells. The use of
freshly isolated human monocytes instead of monocytic/
macrophage cell lines did not increase this percentage.
Although this is better than the injection of free virus, and a
significant antitumor effect has been recently reported using
a similar approach (Muthana et al., 2011), there is clearly
room for improvement. The challenge is evident in immu-
nocompetent hosts such as Syrian hamsters. Apart from the
barrier imposed by the immune system (Bortolanza et al.,
2009a), differences in the anatomy of animals and the ar-
chitecture of tumors may contribute to the blockade of tumor
transduction. We increased 10–20 times the number of cells
in hamsters versus mice to compensate for the difference in
body weight. Although we cannot rule out that injection of
larger numbers of virus-loaded cells could lead to the same
degree of transgene expression in tumors, the ratio of tumor/
liver transduction would be probably unfavorable. Ahmed
et al. have recently described the use of MSCs as carriers for
OAVs in another semi-permissive model (cotton rat) (Ahmed
et al., 2010). Direct comparison between liver/tumor trans-
duction was not performed in this study, but they report
substantial persistence of the cells in the liver upon systemic
administration.
In a different approach, OAVs expressing therapeutic
genes with systemic antitumor effect may be administered
locally in accessible lesions, using new interventional radi-
ology techniques. In this case, carrier cells may play an im-
portant role in protection from NAbs and allow multiple
rounds of transgene expression. Therefore, we focused on the
hamster model and evaluated the ability of monocytes to
improve tumor transduction in the context of local admin-
istration in hepatic tumors. An important concept in vir-
otherapy is the efficacy of repeated administrations of OVs in
solid tumors. This issue is controversial both in animal
models and in clinical reports. Our data indicate that a single
intratumoral injection of Ad-WTLuc causes a sharp increase
in NAbs that are able to block the effect of subsequent doses.
The titer of NAbs rises as early as one week after injection
(not shown) and peaks approximately at three weeks. This is
in agreement with the clinical experience reported with a
FIG. 7. Monocytes improve the antitumor effect of an OAV-expressing IL-12 in preimmunized Syrian hamsters. (A)
Schematic representation of the experiment. Syrian hamsters received an intravenous injection of Ad5 (5· 108 iu) for im-
munization. Twenty days later, tumors were established by intrahepatic inoculation of HaP-T1 cells (day 0). Six days later,
tumor formation was confirmed by ultrasound and animals received an intratumoral injection of saline solution (control) or
2.5 · 107 iu of Ad-IL12G (virus) or 1· 107 HM-1 cells infected ex vivo with Ad-IL12G at MOI 100 (HM-1). Treatments were
repeated at days 8 and 13, as indicated. Blood collection was carried out before initiation of treatment and after each tumor
inoculation to determine concentration of IL-12 (B) and titer of anti-adenovirus NAbs (C). Hamsters were sacrificed 3 weeks
after initiation of treatment and tumors were directly measured at necropsy (D). *p < 0.05.
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first-generation adenovirus expressing the suicide gene thy-
midine kinase in hepatocellular carcinoma (Penuelas et al.,
2005).
Apart from the problem of re-administration, pre-existing
NAbs against Ad5 is a potential drawback for the efficacy of
OAVs. Experimental immunization with Ad5 in the hamster
model recapitulated the situation observed with a significant
segment of the adult population (Sprangers et al., 2003;
Thorner et al., 2006; Appaiahgari et al., 2007; Sun et al., 2011).
NAbs may differ in many characteristics such as affinity and
isotype, but we used a functional assay (luciferase-based
virus neutralization assay) to harmonize results. The titers
described here are apparently higher than those usually re-
ported in humans, probably because we considered the 50%
inhibition threshold (instead of 90%) to increase the sensi-
tivity of the assay (Sprangers et al., 2003). Importantly,
monocytes protected Ad-WTLuc from NAbs and enabled
tumor transduction in preimmunized animals and in re-
peated administrations.
Finally, we evaluated the therapeutic potential of mono-
cytes as carrier cells using the Ad-IL12G virus. We had de-
termined in previous studies that the antitumor effect of this
kind of OAV depends mainly on the expression of the
transgene (Bortolanza et al., 2009b). The HaP-T1 tumor
model used in this work is very aggressive and causes death
of the animals approximately one month after hepatic cell
implantation. In addition, hamsters were preimmunized
with Ad5. Under these circumstances, administration of the
free virus had virtually no antitumor effect, and detection of
the transgene was negligible in serum. In contrast, mono-
cytes allowed at least three productive administrations and
achieved a significant reduction in the growth of pancreatic
tumors.
In summary, we conclude that the most immediate ap-
plication of carrier cells such as monocytes in virotherapy is
the repeated local delivery of OVs expressing therapeutic
transgenes with systemic antitumor effect.
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